The complexity of tissue-type plasminogen activator: can serine protease inhibitors help in stroke management?

Area of Science:

• Neuroscience
• Biochemistry
• Pharmacology

Background:

• Stroke is a leading cause of death and disability globally, posing a significant healthcare challenge.
• Current stroke therapies, like tissue-type plasminogen activator (tPA), show limitations despite animal model efficacy.
• tPA, while effective for reperfusion, can paradoxically exacerbate neuronal injury through excitotoxicity.

Purpose of the Study:

• To review the multifaceted roles of tPA in stroke pathophysiology.
• To discuss strategies for improving current clinical stroke management.
• To explore the potential of targeting tPA's detrimental effects using serpins.

Main Methods:

• Review of existing literature on tPA in stroke.
• Analysis of molecular mechanisms underlying tPA-induced excitotoxicity.
• Discussion of therapeutic implications of serpins in stroke.

Main Results:

• tPA plays a dual role in stroke, aiding reperfusion but also contributing to parenchymal damage.
• Experimental stroke therapies targeting tPA have largely failed in clinical trials.
• Endogenous serine protease inhibitors (serpins) show promise in mitigating tPA's deleterious actions.

Conclusions:

• tPA's complex role in stroke necessitates a nuanced therapeutic approach.
• Targeting excitotoxic pathways activated by tPA could improve stroke outcomes.
• Serpins represent a potential therapeutic strategy to enhance tPA's safety and efficacy.